Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetic SignaturesASX:GSS -1.49% Forward Dividend Yield % is 0.00% as of Jul. 21, 2026. The stock has 4 warning signs investors should review. Among 62 Medical Diagnostics & Research companies, Genetic Signatures ranks worse than 1612901.61% on this metric.
As of today (2026-07-21), the Forward Annual Dividend Yield of Genetic Signatures is 0.00%.
As of today (2026-07-21), the Trailing Annual Dividend Yield of Genetic Signatures is 0.00%.
ASX:GSS's Forward Dividend Yield % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.095 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Genetic Signatures Forward Dividend Yield % Related Terms
ASX:GSS vs TMO, DHR, IDXX: Forward Dividend Yield % Comparison
For the Diagnostics & Research subindustry, Genetic Signatures's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Signatures Forward Dividend Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Signatures's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Genetic Signatures's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Genetic Signatures (ASX:GSS) has a Forward Dividend Yield % of 0.00% as of Jul. 21, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Genetic Signatures and its competitors. According to the industry distribution chart, Genetic Signatures ranks #999999 out of 62 companies in the Medical Diagnostics & Research industry.
Is Genetic Signatures' Forward Dividend Yield % too high?
Genetic Signatures' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Genetic Signatures ranks #999999 out of 62 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Genetic Signatures' Forward Dividend Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Signatures ranks #999999 out of 62 companies for Forward Dividend Yield %. This places Genetic Signatures in the lower half of its industry. The industry median Forward Dividend Yield % is 2.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Diagnostics & Research company?
The median Forward Dividend Yield % among Medical Diagnostics & Research companies is 2.10, based on 62 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Genetic Signatures and its competitors. For the Medical Diagnostics & Research industry, the median Forward Dividend Yield % is 2.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Signatures's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Signatures stock overvalued right now?
Based on GuruFocus' analysis, Genetic Signatures (ASX:GSS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.38, compared to a current price of A$0.07 — trading 82.6% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Genetic Signatures (ASX:GSS), the current Forward Dividend Yield % is 0.00% as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genetic Signatures Ltd is a specialist molecular diagnostics company, specializing in syndromic multiplex real-time PCR testing. The company offers products for the routine detection of infectious diseases and pathogens. It has three operating segments based on regions: Asia Pacific, EMEA, and Americas. It generates the majority of its revenue from the Asia Pacific region. The group's operations are based in Australia, with sales and support teams in the UK, Germany, and the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:GSS has been successfully added to your 
